Physician profile
Paul Mcclain
NPI 1235470261
$2,655.09
in general payments reported to CMS, 2019-2025
10 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.53 · 2022: $171 · 2023: $262 · 2024: $274 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.00 |
| Travel and Lodging | $877.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,164.21 | 2025 | |
| Boston Scientific Corporation | $591.31 | 2023-2025 | Axonics, Moses, Lithovue |
| Procept Biorobotics Corporation | $298.11 | 2025 | |
| Urogen Pharma, INC. | $150.32 | 2023 | Jelmyto |
| Intuitive Surgical, INC. | $140.51 | 2024 | |
| Medtronic, INC. | $90.26 | 2022 | |
| Janssen Biotech, INC. | $89.04 | 2025 | Erleada |
| Ambu INC. | $80.89 | 2022 | |
| Karl Storz Endoscopy-America | $31.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.91 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.